How Has the Vaxneuvance Market Evolved Historically and What is its Current Size?
The vaxneuvance market has seen considerable growth due to a variety of factors.
• The market size of vaxneuvance has recently expanded at a XX (HCAGR). Its anticipated expansion will see it rise from $XX million in 2024 to $XX million in 2025, with a compound annual growth rate (CAGR) of XX%.
Factors contributing to the growth during the historic period include the escalating prevalence of pneumococcal diseases, an increasing aging population, supportive regulatory approvals, an increase in government funding for vaccinations, and a surge in travel and globalization.
What is the Forecasted Market Size and CAGR for the Vaxneuvance Market?
The vaxneuvance market is expected to maintain its strong growth trajectory in upcoming years.
• Predictions indicate the Vaxneuvance market is on a trajectory of growth with an expected compound annual growth rate (CAGR) of XX% in the coming years. By 2029, the market value is projected to reach $XX million.
This anticipated growth during the forecast period can be traced back to several factors such as the increasing prevalence of chronic conditions, a rise in antimicrobial resistance, an escalation in respiratory infections in children, increasing instances of immunocompromised populations, and growing investment in healthcare. Several trends for the projected period include the evolution of needle-free systems for vaccine delivery, advancements in technologies supporting cold-chain, AI-powered optimization of supply chains, integration of immunisation tracking with digital health records, and breakthroughs in adjuvant systems designed to enhance immune response.
What Key Factors and Trends Are Driving The Growth Vaxneuvance Market?
The anticipated rise in pneumonia cases is likely to fuel the growth of the vaxneuvance market. Pneumonia refers to an infection causing inflammation in one or both lung's air sacs, often filled with fluid or pus, leading to symptoms like coughing, fever, and difficulty in breathing. Factors such as viral and bacterial infections, compromised immune systems, air pollution, and the growing elderly population contribute to the prevalence of pneumonia, making individuals more prone to respiratory infections. Vaxneuvance assists patients by shielding them from pneumonia induced by 15 strains of Streptococcus pneumoniae, mitigating the risk of severe infections and their associated complications. For example, in 2024, the average Pneumonia GAPPD (Global Action Plan for Pneumonia and Diarrhea) score across 15 countries was reported to be 56% by Johns Hopkins University, a US-based research institution, marking a 2% increase from 54% in 2023. Thus, the high prevalence of pneumonia is propelling the vaxneuvance market's growth.
What Are The Market Segments In The Vaxneuvance Market?
The vaxneuvance market covered in this report is segmented –
1) By Indication: Pneumonia, Meningitis, Sepsis, Bacteremia, Otitis Media
2) By Distribution Channel: Pharmacies, Hospitals
3) By End User: Adults, Children, Geriatric Population
Pre-Book The Vaxneuvance Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
How Are New Trends Impacting The Size Of The Vaxneuvance Market?
A primary trend in the vaxneuvance market revolves around the expansion of vaccine indications to increase its target patient group. These extended indications respond to unmet healthcare requirements and augment the functional efficacy of the vaccine in hindering pneumococcal illnesses in varying age categories. For instance, in June 2022, Merck & Co. Inc., a pharmaceutical corporation based in the US, disclosed that the US Food and Drug Administration (FDA) has broadened the approval of vaxneuvance to children as young as 6 weeks up to 17 years old for the prevention of invasive pneumococcal disease induced by 15 serotypes. This approval accentuates its clinical importance but warns against administration to those with severe allergic reactions to its components.
Who Are the Key Players In The Vaxneuvance Market?
Major companies operating in the vaxneuvance market are:
• Merck & Co. Inc.
What Are The Regional Insights Into The Vaxneuvance Market?
North America was the largest region in the vaxneuvance market in 2024. The regions covered in the vaxneuvance market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
